Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $530.11, generating $5.04 million. She retains 324,443 shares, with ownership declining 2.84%.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analysts maintain a “Moderate Buy” consensus with a $646 price target; 11 analysts rate the stock Buy and two rate it Hold. Institutional investors own 94.08% of the company.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $530.11, for a total transaction of $5,036,045.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $171,990,478.73. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
United Therapeutics Price Performance
Shares of NASDAQ UTHR opened at $515.50 on Wednesday. The company has a market cap of $22.11 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 1.79 and a beta of 0.59. United Therapeutics Corporation has a 12 month low of $292.34 and a 12 month high of $609.35. The company has a 50-day simple moving average of $538.63 and a 200-day simple moving average of $535.46.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics's revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted $6.41 EPS. On average, analysts anticipate that United Therapeutics Corporation will post 26.32 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the stock. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. Weiss Ratings cut United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, July 31st. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Bank of America decreased their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Finally, Wells Fargo & Company upgraded United Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $646.00.
Check Out Our Latest Research Report on UTHR
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Torren Management LLC bought a new position in United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC grew its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics during the fourth quarter worth approximately $31,000. Institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
